-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
Ebola trial vaccines heading to Uganda: WHO
Three candidate vaccines against the strain of Ebola wreaking havoc in Uganda will be shipped to the East African country next week for trials, the World Health Organization said Wednesday.
Since Uganda declared an Ebola outbreak on September 20, cases have spread across the country, including to the capital Kampala, and have claimed 55 lives, with 22 more believed to have died.
Uganda has been struggling to rein in the outbreak caused by the Sudan strain of the virus, for which there is currently no vaccine.
But UN health agency chief Tedros Adhanom Ghebreyesus told reporters that vaccine trials would soon begin.
Speaking from the G20 summit in Indonesia, he said a WHO committee of external experts had evaluated candidate vaccines and determined "all three should be included in the planned trial in Uganda".
The WHO and the Ugandan health ministry accepted the committee's recommendation, he said, adding: "We expect the first doses of vaccine to be shipped to Uganda next week."
The WHO hailed the "incredibly fast collaboration" to reach this point.
"Since the outbreak began, the government of Uganda, together with researchers, funders, companies, regulatory authorities and other experts has been working under a global effort coordinated by WHO to accelerate the development and deployment of vaccines for use in trials," Tedros pointed out.
- 'Uncertainty' -
The candidates include a vaccine developed by Oxford University and the Jenner Institute in Britain, and another from the Sabin Vaccine Institute in the United States.
The third candidate came through the International AIDS Vaccine Initiative (IAVI), WHO said.
They will be used in a so-called ring vaccination trial, where all contacts of confirmed Ebola patients, and contacts of contacts are jabbed along with frontline and health workers.
"We have received written confirmation from the developers that sufficient vaccines and sufficient number of doses will be available for the clinical trial, and beyond if necessary," Ana Maria Henao Restrepo, one of WHO's heads of research and development, told reporters.
There is meanwhile concern that progress being made to slow the spread of Ebola even without the jabs could complicate the planned trials.
Such trials can only be run when there is fairly rapid transmission under way of Ebola, a haemorrhagic fever that spreads through close contact with bodily fluids and that is often deadly.
"We have uncertainty... about the evolution of the outbreak," Henao Restrepo said, acknowledging that it remained unclear "how many rings can be formed as part of the trial."
But she stressed that all those involved were committed to pushing ahead with randomised trials in a bid to "generate robust evidence that will allow us to know if one or more of them has the efficacy we hope they have."
- 'Controllable without vaccines' -
WHO emergencies director Michael Ryan insisted it was important to get started, even if lower transmission levels might make it impossible to complete the trials immediately.
"If we have to do this in one or two steps, we will," he told reporters.
At the same time, Ryan emphasised that "this epidemic is controllable without vaccines."
Experience from the far more frequent outbreaks of the Ebola Zaire strain -- for which a vaccine was developed after the massive West Africa outbreak that started in 2013 -- shows that "you can get control much quicker using effective vaccines," he told reporters.
"But just to reassure people in Uganda, we can stop this outbreak based on the current efforts."
Tedros agreed, insisting that Kampala's efforts had already "slowed transmission in most districts."
He pointed out that two districts had not reported any cases for 42 days, "indicating the virus is no longer present in those districts".
But he warned that Jinja had also reported its first case in the past week, "becoming the ninth district to be affected".
In addition to the candidate vaccines, the WHO said a separate group of experts had selected two investigational therapeutics for a trial, which still requires a green light from WHO and Ugandan authorities.
A.Taylor--AT